Logo image of JAGX

JAGUAR HEALTH INC (JAGX) Stock Fundamental Analysis

NASDAQ:JAGX - Nasdaq - US47010C8055 - Common Stock - Currency: USD

0.8561  -0.03 (-2.86%)

After market: 0.85 -0.01 (-0.71%)

Fundamental Rating

2

JAGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. JAGX has a bad profitability rating. Also its financial health evaluation is rather negative. JAGX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

JAGX had negative earnings in the past year.
In the past year JAGX has reported a negative cash flow from operations.
JAGX had negative earnings in each of the past 5 years.
JAGX had a negative operating cash flow in each of the past 5 years.
JAGX Yearly Net Income VS EBIT VS OCF VS FCFJAGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of JAGX (-64.55%) is worse than 69.19% of its industry peers.
JAGX has a Return On Equity of -234.48%. This is in the lower half of the industry: JAGX underperforms 74.05% of its industry peers.
Industry RankSector Rank
ROA -64.55%
ROE -234.48%
ROIC N/A
ROA(3y)-93.37%
ROA(5y)-98.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAGX Yearly ROA, ROE, ROICJAGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

With an excellent Gross Margin value of 80.11%, JAGX belongs to the best of the industry, outperforming 84.86% of the companies in the same industry.
In the last couple of years the Gross Margin of JAGX has grown nicely.
JAGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.75%
GM growth 5Y16.19%
JAGX Yearly Profit, Operating, Gross MarginsJAGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, JAGX has less shares outstanding
The number of shares outstanding for JAGX has been reduced compared to 5 years ago.
JAGX has a better debt/assets ratio than last year.
JAGX Yearly Shares OutstandingJAGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
JAGX Yearly Total Debt VS Total AssetsJAGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

JAGX has an Altman-Z score of -9.06. This is a bad value and indicates that JAGX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.06, JAGX is not doing good in the industry: 72.43% of the companies in the same industry are doing better.
JAGX has a Debt/Equity ratio of 1.35. This is a high value indicating a heavy dependency on external financing.
JAGX has a Debt to Equity ratio of 1.35. This is in the lower half of the industry: JAGX underperforms 76.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Altman-Z -9.06
ROIC/WACCN/A
WACC3.97%
JAGX Yearly LT Debt VS Equity VS FCFJAGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

JAGX has a Current Ratio of 1.84. This is a normal value and indicates that JAGX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of JAGX (1.84) is worse than 63.24% of its industry peers.
JAGX has a Quick Ratio of 1.36. This is a normal value and indicates that JAGX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.36, JAGX is not doing good in the industry: 71.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.36
JAGX Yearly Current Assets VS Current LiabilitesJAGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

JAGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.45%, which is quite impressive.
The Revenue has decreased by -2.25% in the past year.
Measured over the past years, JAGX shows a quite strong growth in Revenue. The Revenue has been growing by 17.19% on average per year.
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.82%
Revenue 1Y (TTM)-2.25%
Revenue growth 3Y1.32%
Revenue growth 5Y17.19%
Sales Q2Q%10.49%

3.2 Future

The Earnings Per Share is expected to grow by 22.40% on average over the next years. This is a very strong growth
Based on estimates for the next years, JAGX will show a very strong growth in Revenue. The Revenue will grow by 110.13% on average per year.
EPS Next Y86.28%
EPS Next 2Y28.32%
EPS Next 3Y22.4%
EPS Next 5YN/A
Revenue Next Year21.35%
Revenue Next 2Y30.37%
Revenue Next 3Y33.49%
Revenue Next 5Y110.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JAGX Yearly Revenue VS EstimatesJAGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
JAGX Yearly EPS VS EstimatesJAGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -10M -20M -30M -40M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

JAGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JAGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAGX Price Earnings VS Forward Price EarningsJAGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAGX Per share dataJAGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

JAGX's earnings are expected to grow with 22.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.32%
EPS Next 3Y22.4%

More info and screens

0

5. Dividend

5.1 Amount

JAGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JAGUAR HEALTH INC

NASDAQ:JAGX (2/21/2025, 8:00:02 PM)

After market: 0.85 -0.01 (-0.71%)

0.8561

-0.03 (-2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-31 2025-03-31/amc
Inst Owners2.14%
Inst Owner Change-0.19%
Ins Owners0.28%
Ins Owner Change1.18%
Market Cap11.21M
Analysts85.71
Price Target6.12 (614.87%)
Short Float %7.34%
Short Ratio1.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-86.75%
Min EPS beat(2)-230.06%
Max EPS beat(2)56.56%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-22.38%
Min Revenue beat(2)-22.63%
Max Revenue beat(2)-22.12%
Revenue beat(4)0
Avg Revenue beat(4)-20.11%
Min Revenue beat(4)-22.63%
Max Revenue beat(4)-13.6%
Revenue beat(8)3
Avg Revenue beat(8)-5.49%
Revenue beat(12)4
Avg Revenue beat(12)-6.77%
Revenue beat(16)5
Avg Revenue beat(16)-20.25%
PT rev (1m)0%
PT rev (3m)-58.62%
EPS NQ rev (1m)55.69%
EPS NQ rev (3m)38.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)-14.33%
Revenue NQ rev (3m)-20.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.07
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-19.88
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-2.22
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS0.8
BVpS1.23
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.55%
ROE -234.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.11%
FCFM N/A
ROA(3y)-93.37%
ROA(5y)-98.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.75%
GM growth 5Y16.19%
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 1.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.83%
Cap/Sales 0.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.36
Altman-Z -9.06
F-Score4
WACC3.97%
ROIC/WACCN/A
Cap/Depr(3y)28.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.72%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.82%
EPS Next Y86.28%
EPS Next 2Y28.32%
EPS Next 3Y22.4%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.25%
Revenue growth 3Y1.32%
Revenue growth 5Y17.19%
Sales Q2Q%10.49%
Revenue Next Year21.35%
Revenue Next 2Y30.37%
Revenue Next 3Y33.49%
Revenue Next 5Y110.13%
EBIT growth 1Y9.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.52%
OCF growth 3YN/A
OCF growth 5YN/A